PDL BioPharma, Inc.
http://www.pdl.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PDL BioPharma, Inc.
US FDA Open To Cell Therapy ‘Assessment Aid’ That Could Speed Development Of Next-Gen Cancer Drugs
A framework for sponsors and the FDA to discuss ways to extrapolate existing data to support a new cell therapy could cut the time to approval.
The Cancer Cell Therapy Showdown: CAR-Ts Versus CAR-NKs
Will CAR-NK cell therapies overshadow traditional CAR-T options for the treatment of some cancers? While preliminary data for CAR-NKs point to enhanced safety and solid tumor penetration, oncologists and executives discuss the pros and cons of these two approaches to cell therapy.
Fresenius Pushes Kabi Even Higher As Former Sandoz Exec Named CEO
The Fresenius group spoke at length about its core Fresenius Kabi business during the company’s year-end financial call, not least its under pressure IV drugs in the US.
Akeso's Xia Looks Beyond Summit Deal To Independent Global Development, Sales
Last December, China's Akeso struck a major agreement worth up to $5bn with Summit Therapeutics, which set a new record in terms of total deal value for a single asset in the Chinese biopharma sector. Akeso founder and CEO Michelle Xia is now planning to pursue a more independent path in taking the firm global.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Eos Biotechnology, Inc.
- LENSAR, Inc.
- Noden Pharma DAC
- Noden USA
- Protein Design Labs, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice